Olema Pharmaceuticals CFO Jason O’Byrne files initial beneficial ownership statementPUBT·Aug 13 at 03:42 PMOLMA-2.43%
JPMorgan Chase & Co. Issues Pessimistic Forecast for Olema Pharmaceuticals (NASDAQ:OLMA) Stock PriceMarket Beat·Aug 13 at 10:36 AMOLMA-2.43%
Olema Pharmaceuticals (NASDAQ:OLMA) Price Target Lowered to $59.00 at CitigroupMarket Beat·Aug 11 at 02:36 PMOLMA-2.43%
Olema Pharmaceuticals Stock Falls as Pivotal Breast Cancer Data Pushed Into 2027benzinga_article·Aug 11 at 01:27 PMOLMA-2.43%
Olema Pharmaceuticals: Buy Rating Reiterated as Palazestrant Phase 3 Catalysts Loom; $24 Price Target MaintainedTip Ranks·Aug 10 at 10:35 PMOLMA-2.43%
12 Health Care Stocks Moving In Monday's After-Market Sessionbenzinga_article·Aug 10 at 04:06 PMSANA-3.32%ALC+0.10%
Olema Pharmaceuticals (NASDAQ:OLMA) Releases Earnings Results, Misses Estimates By $0.08 EPSMarket Beat·Aug 10 at 03:41 PMOLMA-2.43%
Olema Oncology Reports Second Quarter 2026 Financial and Operating ResultsUnusual Whales·Aug 10 at 03:02 PMOLMA-2.43%
Olema grants stock options for 254,540 shares to seven new employees under inducement planPUBT·Aug 4 at 04:32 PMOLMA-2.43%
Olema Pharmaceuticals (OLMA) Expected to Release Quarterly Earnings on MondayMarket Beat·Aug 3 at 08:56 AMOLMA-2.43%
